Completed A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer NCT01268150 Conditions Breast Diseases, Breast Neoplasms, Locally Recurrent, +5 more Locations University of Miami — Miami, Florida, United States Augusta Oncology Associates — Augusta, Georgia, United States Central Georgia Cancer Care — Macon, Georgia, United States Northwest Georgia Oncology Centers, P.C. — Marietta, Georgia, United States View all 17 locations View more locations Show fewer locations Loading locations... View Trial Details
